ArticleCureus2025
Clinical Presentation and Long-Term Outcomes of Lupus Nephritis in Palestine: A Multicenter Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSystemic lupus erythematosus (SLE) is a systemic autoimmune disease that frequently affects the kidneys, resulting in lupus nephritis (LN). LN significantly impacts patient morbidity and mortality, with varying clinical presentations and treatment responses across populations. This retrospective study aimed to describe the demographic, clinical, laboratory, and histopathological features of Palestinian patients with biopsy-confirmed LN, and to assess treatment strategies and patient outcomes.
methodsThis multicenter retrospective study was conducted between November 2023 and May 2024 across three major Palestinian hospitals: An-Najah National University Hospital, Al-Watani Hospital, and Al-Makassed Hospital. We reviewed the medical records of patients with SLE who underwent renal biopsy between July 2016 and December 2023. A total of 78 patients with SLE who had biopsy-confirmed LN were included. For each patient, demographic characteristics (age, sex, family history), clinical features (comorbidities, systemic manifestations), and laboratory parameters (serum creatinine, blood urea nitrogen (BUN), proteinuria, hematuria, complement levels, antinuclear antibody, and anti-double-stranded DNA) were extracted from medical records. Histopathological findings were reviewed using light microscopy and immunofluorescence. Treatment modalities, including corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and additional immunosuppressive agents, were documented. Outcomes were categorized into remission, progression to end-stage renal disease (ESRD), or death. Statistical analyses were performed using IBM SPSS version 22 (IBM Corp., Armonk, NY), with descriptive statistics applied to summarize patient characteristics and Fisher's exact test employed to examine associations between variables and outcomes.
resultsA total of 78 patients with biopsy-confirmed LN were analyzed, of whom 63 (80.8%) were females. The most common age group was 15-29 years (46.2%). Hypertension (30.7%) and diabetes mellitus (8.0%) were the leading comorbidities. Proteinuria was present in 90.8% of patients, with nephrotic-range proteinuria (>3.5 g/day) in 48.7%, while hematuria was observed in 70.1%. Hypocomplementemia was common, with low C3 in 61.3% and low C4 in 62.1%. The most frequent biopsy classes were class IV (47.1%) and class III (22.9%). Regarding outcomes, 71 patients (91.0%) remained in remission with ongoing treatment, five patients (6.4%) progressed to ESRD requiring dialysis, and two patients (2.6%) died due to LN complications. Male sex was significantly associated with dialysis dependency (p < 0.001), while hypertension was also strongly linked to dialysis outcomes (p = 0.035). Elevated serum creatinine (>1.5 mg/dL) and BUN (>20 mg/dL) were strongly associated with both ESRD and mortality (p < 0.001 and p = 0.01, respectively).
conclusionThis study sheds light on LN patients in Palestine, highlighting the high morbidity and mortality rates. It emphasizes early detection and aggressive management, especially in patients with hypertension and elevated creatinine levels, to improve outcomes and reduce progression to ESRD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.